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Protein tyrosine phosphatases (PTPs) play a critical
role in regulating cellular functions by selectively
dephosphorylating their substrates. Here we present
22 human PTP crystal structures that, together with
prior structural knowledge, enable a comprehensive
analysis of the classical PTP family. Despite their
largely conserved fold, surface properties of PTPs
are strikingly diverse. A potential secondary sub-
strate-binding pocket is frequently found in phospha-
tases, and this has implications for both substrate
recognition and development of selective inhibitors.
Structural comparison identified four diverse cata-
lytic loop (WPD) conformations and suggested
a mechanism for loop closure. Enzymatic assays re-
vealed vast differences in PTP catalytic activity and
identified PTPD1, PTPD2, and HDPTP as catalytically
inert protein phosphatases. We propose a ‘‘head-to-
toe’’ dimerization model for RPTPg/z that is distinct
from the ‘‘inhibitory wedge’’ model and that provides
a molecular basis for inhibitory regulation. This phos-
phatome resource gives an expanded insight into
intrafamily PTP diversity, catalytic activity, substrate
recognition, and autoregulatory self-association.
INTRODUCTION
Protein tyrosine phosphorylation is a dynamic process governed
by the balanced action of tyrosine kinases and protein tyrosine
phosphatases (PTPs) and is a critical event in the regulation of
numerous physiological processes (Pao et al., 2007; Tonks,
2006) . Dysregulation of PTPs is associated with a multitude of
diseases, and many members of the PTP family have been
recognized as potential therapeutic targets (Tautz et al., 2006).
The human genome contains 107 PTPs, with the class I
cysteine-based PTPs constituting the largest group. This group
can be further subdivided into 61 dual-specificity phosphatases
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which are the focus of this study. Classical PTPs have been
further subdivided into receptor (R1–R8) and nontransmem-
brane (NT1–NT9) subgroups (Alonso et al., 2004; Andersen
et al., 2001). Twelve receptor PTPs have two catalytic domains
(tandem domains), while the remaining PTPs all have a single
catalytic phosphatase domain. In tandem-domain receptor
protein tyrosine phosphatases (RPTPs), it is the PTP (D1) domain
adjacent to the plasma membrane that displays catalytic activity
while the PTP (D2) domain is either inactive or has negligible
catalytic activity (Andersen et al., 2001). The functional role of
the D2 domain has not yet been defined although possible roles
in regulating RPTP stability, specificity, and dimerization have
been suggested. Furthermore, all RPTPs, with the exception of
RPTPa and RPTP3, contain large and diverse extracellular
regions that regulate cell contacts and adhesion (Aricescu
et al., 2007).
The 280 residue PTP catalytic domain consists of an a/b
structure, and biochemical and structural studies have led to
a detailed understanding of the catalytic mechanism (Barford
et al., 1994; Zhang, 2002). Key features of the domain include
the PTP signature motif, the mobile Trp-Pro-Asp ‘‘WPD’’ loop
that in the closed conformation positions the conserved and
catalytically important aspartate residue, and the phosphotyro-
sine recognition loop.
PTPs exhibit exceptional substrate specificity in vivo, which is
conveyed both by the catalytic domain and other regulatory
mechanisms including restricted subcellular localization, post-
translational modification events (e.g., phosphorylation), specific
tissue distribution, and accessory or regulatory domains (e.g.,
KIM motifs or SH2 domains) (Tiganis and Bennett, 2007). Within
the catalytic domain, the phosphotyrosine recognition loop
(between a1–b1) contributes to the selective recognition of
phosphotyrosine over phosphoserine/threonine, and two non-
conserved residues following the conserved tyrosine in this
loop are important in substrate interactions. A secondary phos-
photyrosine (pY) binding site, proximal to the active site, has
been identified in PTP1B. The secondary site is accessed from
the active site via a channel referred to as the ‘‘gateway’’ region
(Peters et al., 2000; Puius et al., 1997; Salmeen et al., 2000). The
secondary pY-binding pocket has enabled the development of
high-affinity inhibitors that target both pY-binding sites (Tautz
et al., 2006).
A variety of mechanisms for regulation of PTP function have
been reported, including inactivation of receptor PTPs by dimer-
ization, reversible oxidation, and regulation via extracellular
ligands and phosphorylation (Tonks, 2006). Dimerization as
a control mechanism was first suggested based on structural
studies on the membrane-proximal D1 domain of RPTPa and
EGF receptor/CD45 chimeras (Bilwes et al., 1996; Desai et al.,
1993). The structure revealed a dimeric assembly in which an
inhibitory N-terminal helix-turn-helix wedge motif occluded the
active site of the interacting catalytic domain. Subsequently,
RPTPa and a number of other PTP domains have been shown
to homodimerize at the cell surface resulting in inactivation
(Jiang et al., 2000).
Here we report the crystal structures of 22 PTP domains,
including two tandem-domain RPTP structures and a detailed
structural comparison of this protein family. The generated struc-
tures include at least one member of each PTP subgroup and
thereby provide a comprehensive coverage of the classical
phosphotyrosine-specific PTPome. This phosphatome resource
gives an expanded insight into intrafamily PTP diversity, catalytic
activity, substrate recognition, and autoregulatory self-associa-
tion and supports a ‘‘head-to-toe’’ dimerization model for
RPTPg/z that provides a molecular basis for inhibitory regulation
of this subgroup.
RESULTS
In this study we used a large-scale structural comparison to
identify shared as well as target-specific structural features of
members of the classical PTP family. A prerequisite for a conclu-
sive structural intrafamily comparison is a comprehensive
coverage of the analyzed protein family. To this end, we deter-
mined 22 catalytic domain structures of the human PTP family
including 16 not published previously (Supplemental Data avail-
able online). Combined with other structure determination efforts
(see http://ptp.cshl.edu/ and Almo et al., 2007), the available
structures now provide high-resolution information for at least
one member of each of the main receptor and nontransmem-
brane subgroups across the classical PTPome. The catalytic
domains of the remaining PTPs of unknown structure are more
than 49% identical in sequence to their closest structure-deter-
mined family member allowing the construction of reliable
homology models. The structural coverage of the PTP family is
outlined in the phylogenetic tree shown in Figure 1A. We also
report here structures of two tandem-domain RPTPs, RPTP3
and RPTPg, revealing the domain organization for the PTP
subgroups R4 and R5. The novel structures discussed here
were refined at high resolution (average resolution of 2.0 A˚ and
satisfactory stereochemistry; Supplemental Data).
Examination of the constructed phylogenetic tree (Figure 1A)
revealed that the D2 domains from the R2A and R4 subgroups
are most closely related to their respective D1 domains, sug-
gesting a gene duplication event, while the D2 domains from
RPTPg, RPTPz, RPTPm, RPTPk, RPTPr, and RPTPl cluster
independently of their D1 domains and appear to have a distinct
evolutionary root.Superimposition of all known individual PTP D1 and D2
domain structures showed that PTPs fold into a single domain
of b sheets flanked by a helices and have a highly conserved
topology. The key structural features are highlighted in Figure 1B.
Superimposition of all five tandem-domain RPTP structures
(CD45, LAR, RPTPs, RPTPg, and RPTP3) showed that the orien-
tation of the D1 and D2 domains is highly conserved and root
mean square deviation (rmsd) values of less than 4.4 A˚ were ob-
tained, for each pairwise comparison, considering Ca positions
of both domains (Supplemental Data).
PTPs Have Very Diverse Surface Properties
In contrast to the conserved ternary structure, the surfaces of
PTPs are surprisingly diverse. A structure-based alignment of
all experimental structures for nontransmembrane and receptor
PTPs was used to map conserved residues onto the surface of
PTP1B and the D1 domain of RPTPm, respectively (Figures 1C
and 1D). This mapping of surface residues identified only a few
conserved surface patches comprising loop regions surrounding
the active site (Figure 1C, labels A and C). Conserved surfaces
are formed by the phosphotyrosine recognition loop (KNRY
motif) and by conserved glutamine residues of the Q loop.
Conserved WPD loop residues are largely buried (Figure 1C,
label D). Highly diverse regions including the two residues
following the KNRY motif (Figure 1C, label B) and the topology
of the secondary substrate-binding pocket present in a number
of PTPs (Figure 1C, label F) contribute to defining substrate
specificity. A conserved tyrosine residue (Tyr1019 in RPTPm)
flanking the active site is characteristic for RPTPs (Figure 1D,
label A), and the face opposing the active site contains only
one conserved cleft as already noted (Andersen et al., 2001).
The diverse PTP surface gives rise to significant differences in
surface electrostatic potential, a property that is likely to influ-
ence substrate recognition, association with regulatory proteins,
and regulatory mechanisms such as dimerization (Figure 2). This
diversity, which was first noted by Alonso et al. based on
homology models (Alonso et al., 2004), is apparent not only
between different PTP family members but also within individual
subgroups. However, some diversity in surface potential is intro-
duced by differences in the open or closed states of the active
site (e.g., compare PTP1Bopen/closed conformations; Figure 2),
but such changes are localized only to a small surface area.
Particularly notable within the RPTP group is the significantly
different electrostatic potentials of CD45 and either LAR or
RPTPg. The active site and proximal surface in most PTPNs
are largely electropositive, whereas inmost RPTPs areas of posi-
tive electrostatic potential are mainly localized to the active sites.
Catalytic Loop (WPD) Movement
The dynamics of the opening/closing transition of the WPD loop
has implications for PTP substrate recognition and catalytic effi-
ciency and is also of paramount importance for the development
of selective PTP inhibitors that may recognize a certain loop
conformation. Structural comparisons of all available PTP struc-
tures identified four main WPD loop conformations: a closed
state, an intermediate state, an open state, and an atypically
open state present in STEP, LYP, and GLEPP1 (Figure 3A). The
atypically open state is associated in STEP with a stabilizingCell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc. 353
A B
C
D
Figure 1. Structural Coverage of the PTPome and Surface Diversity
(A) Phylogenetic tree of human PTPD1 andD2 domains indicating crystal structures determined (SGCOxford structures are highlighted in yellow). Details of other
PTP structures can be found at http://www.sgc.ox.ac.uk/research/phosphatases. PTPs are grouped into receptor PTPs (groups R1–R8) and nontransmembrane
PTPs (groupsNT1–NT9). The abbreviated HumanGenomeOrganisation (HUGO: http://www.genenames.org/) gene symbol nomenclature is used in the tree, and
the corresponding common names and PDB codes are provided in Supplemental Data.
(B) Ribbon diagram of PTP1B with labeling of key secondary structural elements. The Ca of the catalytic cysteine residue is shown as a space-filling CPKmodel.
(C) Conserved residues from a structure-based alignment of nonreceptor PTPs mapped onto the surface of PTP1B. Green: highly conserved, light brown:
conserved residue properties only, and gray: nonconserved.
(D) Conserved residues from a structure-based alignment of receptor PTPs mapped onto the surface of RPTPm.310 helix C-terminal to theWPD loop (Eswaran et al., 2006) and in
LYP and GLEPP1 an extra turn of helix a3 following the WPD
loop. The presence of an atypically open state, catalytically non-
active conformation, in three PTPs from different subgroups
suggests that this conformation may have significance for the
family as a whole.
On cocrystallization of a substrate-trapping mutant of STEP
(Cys472Ser) with pY bound to the active site, the WPD loop
was also present in the atypical open state (Figure 3B), indicating
that this conformation is stable and that substrate binding alone
is not sufficient to induce loop closure as initially suggested
based on apo structures and substrate complexes of PTP1B
(Barford et al., 1998). The observation of an open substrate
complex and closed apo structures (Pedersen et al., 2004) raises
the question of the mechanism that triggers loop closure. Struc-
tural comparison revealed that all closed structures share
a tightly bound ‘‘catalytic water’’ molecule coordinated by two
conserved glutamine residues (Gln262 and 266 in PTP1B)
(Figure 3C). In PTP1B this conserved water molecule has been354 Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc.noted previously in a closed apo-structure, in addition to three
water molecules that mimic the presence of oxygen atoms of
a substrate phosphotyrosine (Pedersen et al., 2004). In contrast,
in structures with an open or atypical WPD loop conformation
this water molecule was not observed or was significantly dis-
placed, suggesting that it is a key part of the closure mechanism.
A Secondary Substrate-Binding Pocket Is Present
in Many PTPs
In order to determine whether other PTPs have a secondary
substrate-binding pocket analogous to that found in PTP1B,
we analyzed the structural topology and residue characteristics
of this region. The presence of a secondary substrate-binding
site cannot easily be predicted by sequence comparisons alone
since it depends not only on the characteristics of the residues in
this region but also on the conformation of the loop connecting
helix a20 and helix a1, which we term the ‘‘second-site loop.’’
The great diversity in conformations of this loop is shown
(Figure 4). On the basis of these structural comparisons the
RT(RPTPρ)
Figure 2. Diversity in Surface Electrostatic Potential across the PTPome
Surface representations showing the calculated electrostatic potential (rendered in ICM) of PTP family members from crystal structures (black) and homology
models (red). The colors of surface elements were capped at ±3 kcal/electron units (+3 = blue; 3 = red) when the calculated potentials were transferred to
the surface. The WPD loop conformation is indicated under each structure.PTPs can be grouped into five categories. In the first category
are TCPTP, SHP1, SHP2, BDP1, LYP, PEST, PTPBAS, DEP1,
MEG2, and GLEPP1, which have a ‘‘PTP1B-like’’ accessible
pocket that harbors a basic residue corresponding to Arg24 of
PTP1B (Figure 4 and Supplemental Data). This pocket has the
potential to accommodate pY at the +1 position as in PTP1B
or potentially other acidic or phosphorylated residues in posi-
tions N-terminal to the substrate pY. Also within this category
are RPTPg and RPTPb, which have the secondary pocket with
a basic residue albeit with bulky residues in the gateway region.
In the secondcategory arePTPs inwhichboth thegateway and
the second-site loop are open and accessible as found in the R8
pseudophosphatase group (IA2, IA2b) but a cysteine residue
occupies the position of Arg24. The third category is exemplifiedby theR2Agroup (LAR,RPTPs, andRPTPd) inwhich thegateway
region contains bulky residues that block access to an open
secondary pocket, with an aspartate residue in the position cor-
responding to Arg24. In the fourth category, both the gateway
and secondary pocket are blocked and the inaccessible binding
cavity harbors an aromatic residue or a proline in position of
Arg24. The second-site loop assumes a twisted conformation
in these phosphatases. This architecture is present in the
subgroups NT5 (PTPH1, MEG1), NT6 (PTPD1, PTPD2), R1
(CD45), R2B (RPTPm, RPTPk, RPTPr), and R4 (RPTPa, RPTP3).
In the fifth category, the gateway is open and accessible while
the secondary site is blocked by an aromatic or proline residue
located in theclosed secondary site loop. This scenario is present
in the R7 group phosphatases (PCPTP, STEP, and HEPTP).Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc. 355
Activity of PTPs toward Peptide Substrates
To assess enzymatic activity and substrate selectivity of PTP
catalytic domains, we selected a panel of diverse phosphopep-
tides derived from known regulatory phosphorylation sites and
assayed them against 28 highly purified PTPs (Figure 5). The
peptides were grouped into acidic substrates, mixed acidic-
basic substrates, and basic substrates based on the character-
istics of residues in N- and C-terminal flanking regions of the
phosphorylated site. Specific activity toward the general PTP
substrate DiFMUP was measured and used to standardize the
amount of protein for phosphopeptide assays. PTPs with parti-
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Figure 3. Novel Conformations and Movement of the Catalytic
(WPD) Loop
(A) WPD loop conformations are shown by a PTP representative of each state:
closed (blue, PTP1B, PDB: 1SUG); open (yellow, PTP1B, PDB: 2HNP); and
atypical (magenta, GLEPP1, PDB: 2GJT; STEP, PDB: 2BIJ; Lyp, PDB:
2P6X). The intermediate WPD loop conformation of PCPTP1 (PDB: 2A8B) is
not shown for clarity. Other PTP structures are shown with a thin transparent
line tracing the backbone and are colored according to conformation.
(B) Superimposition of the structure of STEP-C/S in complex with pY (PDB:
2CJZ; gray) and the apo STEP (PDB: 2BIJ; light green) showing that the
WPD loop conformation does not change on substrate binding (pTyr, orange).
The catalytic water molecule (Wa) corresponding to that found in closed struc-
tures is shown.
(C) Superimposition of the structure of STEP-C/S in complex with pY (PDB:
2CJZ; green) and PTP1B with the insulin receptor peptide (PDB: 1G1H; red).
The conserved water molecule found in closed structures is shown: PTP1B
(1SUG, yellow); GLEPP1 (2G59, orange); HePTP (2A3K, black), DEP1 (2NZ6,
magenta). The arrow indicates the position of the displaced water molecule
in STEP-C/S structure.356 Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc.cularly high enzymatic activity against generic substrates were
RPTPs and PTP subgroups R5, R3, NT1, NT2, NT3, NT4, and
NT5. CD45 and members of subgroups R3 and R5 were
extremely promiscuous and dephosphorylated most phospho-
peptides with reasonable activity. The subgroups NT1, NT2,
NT3, and NT5 exhibited a pronounced preference for acidic resi-
dues N-terminal to the phosphorylation site. In PTP1B this selec-
tivity has been explained by substrate peptide interaction with
Arg47 of the pY-recognition loop (Zhang, 2002).
In contrast, RPTPs, the R7 group, and NT4 group PTPs were
quite selective and showed a preference for a sequence derived
from the phosphorylation site in N-cadherin (pY785), a reported
substrate of RPTPs (Siu et al., 2007). Surprisingly, the phospha-
tases PTPD1 and PTPD2were inactive against the entire panel of
phosphopeptides despite displaying a similar level of activity as
CD45 toward DiFMUP. The phosphatase HDPTP was also inac-
tive toward the generic substrate DiFMUP and the entire panel of
phosphopeptides.
Self-Association of PTPs In Vitro
Dimerization of receptor PTPs has been proposed as a key
mechanism of regulation that leads to inhibition of enzymatic
activity. We have used analytical ultracentrifugation (AUC) to
examine the catalytic domain oligomerization of single- and
tandem-domain receptor PTPs from all of the major subgroups.
Surprisingly, sedimentation velocity measurements showed that
all single-domain RPTPs studied (IA2, IA2b, GLEPP1, DEP1, and
STEP) were entirely monomeric in solution (Figure 6A), as were
tandem-domain receptor PTPs (RPTPa, CD45, RPTP3, and
RPTPm) (Figure 6B). The determined molecular masses calcu-
lated from AUC velocity data ranged from 68.5 kDa to
74.2 kDa in agreement with the theoretical mass of monomeric
tandem domains.
In contrast RPTPg showed significant and concentration-
dependent dimerization (Figure 6B). Sedimentation equilibrium
confirmed that RPTPg formed a stable dimer in solution. The
experimental data fit well to a self-association model resulting
in determination of a dissociation constant (KD) of 3.5 ± 0.3 mM.
The correct masses for the monomeric and dimeric protein were
obtained using this analysis and the residuals showed low
systematic deviations (Figure 6C).
RPTPg Dimerizes in a Head-to-Toe Orientation
Analysis of the RPTPg tandem-domain structure revealed that
RPTPg associated with a symmetry-related molecule as
a ‘‘head-to-toe’’ dimer (i.e., with the D1 domain of one molecule
interacting with the D2 domain of a second molecule and vice
versa) (Figure 6D). The interaction between RPTPg monomers
involves extensive electrostatic interactions from the active site
D1 domain of one RPTPg molecule, visible as a highly electro-
positive pocket, interacting with an electronegative surface of
the D2 from the other molecule. The dimer interface covers
1200 A˚2 (5% of the total molecule surface area) and involves
residues from the phosphotyrosine recognition loop, the P loop
at the bottom of the active site cleft, and sheet b6, while the
D2 domain interface involves the loop connecting strands b10–
b11. Multiple hydrogen bonds and salt bridges are involved in
the interaction between the two molecules (Supplemental
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Figure 4. Secondary Substrate-Binding Pockets
(A) Two extreme conformations of the second-site loop are shown (orange) from RPTPg (extended helix) and HEPTP (closed in conformation). The catalytic
cysteine is shown in a space-filling CPK representation, and loops are colored as follows: WPD (magenta), b5/b6 loop (green), and gateway (red). The dually
pTyr phosphorylated insulin receptor peptide (from PDB: 1G1H) is shown superimposed (for reference only) to indicate the position of the secondary
substrate-binding pocket. The positions of Arg24 and gateway residues Met258 and Gly259 of PTP1B are shown in an enlarged view.
(B) Surface topology and electrostatic charge for the active site (pY), gateway region, and secondary pocket (2pY) are shown for each of the five categories with
the dually pTyr phosphorylated insulin receptor peptide superimposed.
(C) Representative second-site loop conformations are shown for each category (see also Supplemental Data). Category I: SHP2, BDP1, LYP; Category II: IA2,
IA2b; Category III: LAR, RPTPs; Category IV: PTPH1, MEG1, PTPD2, CD45; Category V: STEP, HEPTP, PCPTP1.Data). In this dimeric form, the active site of RPTPg is occluded
by the D2 domain of the interacting molecule, suggesting that
dimerization in this conformation would prevent substrate
access leading to suppression of enzymatic activity.
In order to determine whether the molecular mechanism of
dimerization in solution correlates with that observed in the
crystal structure, we mutated residues of the dimer interface
from either the D1 or D2 domains (Figure 6E). In RPTPg mutant
‘‘RKEE’’ residues, Arg958 and Lys960 of the D1 domain were
mutated to glutamic acid, and in mutant ‘‘DDKK’’ residues,
Asp1305 and Asp1306 of the D2 domain were mutated
to lysine. Both the RKEE and DDKK mutants were entirely
monomeric in solution, as assessed by velocity and equilibrium
AUC analysis validating the head-to-toe dimerization model
(Figure 6F).DISCUSSION
This study provides structural information for more than 22
human PTP catalytic domains, thereby completing structural
coverage for all major subgroups of the classical PTP family
and enabling a comprehensive large-scale structural compar-
ison. This resource provides a family-wide insight into catalytic
(WPD) loop dynamics, self-association, and catalytic domain
substrate specificity.
Structural comparisons identified an atypically open WPD
loop conformation in LYP, GLEPP1, and STEP (Eswaran et al.,
2006), suggesting a regulatory role in diverse family members.
This conformation represents an inactive conformation in which
the WPD aspartate is moved far out of the active site. Low crys-
tallographic temperature factors observed in this loop regionCell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc. 357
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Figure 5. Analysis of PTP In Vitro Substrate Specificity
Phosphatase activity of PTP catalytic domains against a panel of phosphopeptides derived from potential physiological substrates. Calculated reactions rates
(Abs360/s) measured over control (a pSer-containing peptide and no peptide) have been color-coded with higher rates represented by darker shades of blue.
Initial linear reaction rates were measured using the EnzCheck coupled continuous spectrophotometric assay over 5 min. Phosphopeptide names are derived
from the SwissProt human gene name and the number of the pY residue. Sequences have been grouped based on sequence characteristics relative to the
position of the pTyr: (A) N-terminal acidic; (B) N-terminal acidic and C-terminal basic; (C) mixed; (D) N-terminal basic and C-terminal acidic; (E) mixed basic;
and (F) controls.suggest that the atypically open conformation is stable, and
multiple crystal forms ruled out that the WPD loop assumed
this conformation as a result of crystal contacts. In protein
kinases, inactive conformations and active site dynamics are
crucial for the regulation of catalytic activity (Huse and Kuriyan,
2002). By analogy this conformation may represent a regulatory
mechanism for PTPs and may find applications in the develop-
ment of selective and potent inhibitors that target PTP inactive
states.
Secondary Substrate-Binding Pockets
The new structural data and analysis presented here suggest
that a secondary substrate-binding pocket, similar to that found
in PTP1B, is present also in SHP2, BDP1, LYP, SHP1, TCPTP,
MEG2, PTPBAS, DEP1, and GLEPP1. Previous structural
studies of PTPBAS also provided evidence of a secondary phos-
photyrosine pocket (Villa et al., 2005). The basic pocket is also
found in the phosphatases RPTPg and RPTPb; however, the
topology of the region differs in these phosphatases in that the358 Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc.gateway region is inaccessible. The hypothesis that SHP1 and
LYP have the potential to interact with phosphoproteins contain-
ing adjacent phosphotyrosines is consistent with reports that
Zap-70 is a substrate of these PTPs (Pao et al., 2007). However,
given that a relatively small number of proteins contain two adja-
cent phosphotyrosines, this pocket in other PTPs may interact
with phosphothreonine, serine, or an acidic residue in a position
N-terminal to the substrate pY. The secondary pocket of PTP1B,
and more recently LYP, has been successfully exploited in the
design of selective bidentate inhibitors (Yu et al., 2007). A similar
inhibitor design strategy may also be used in the design of inhib-
itors of SHP2 for cancer (Chan et al., 2008) and may now be
applied to a much wider subset of PTPs.
Catalytic Activity
Our analysis of phosphatase activity using both a generic
substrate and a panel of phosphopeptides represents a large
set of comparable data across representative PTPs. The specific
activity and phosphopeptide selectivity profile of each PTP
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Figure 6. Self-Association of PTPs and
Dimerization of RPTPg
(A) Sedimentation velocity AUC measurements of
single-domain PTPs: IA2 (red); GLEPP1 (dark
blue); DEP1 (green); IA2b (black); STEP (light
blue). Differential sedimentation coefficient distri-
bution, c(s), is plotted versus the apparent sedi-
mentation coefficient corrected to water at 20C,
s20,w, together with the differential molecular
weight distribution, c(M), versus molecular weight,
M (inset). Experiments were conducted with
a protein concentration of 0.8 mg/ml (24 mM).
(B) Sedimentation velocity AUC measurements of
tandem-domain RPTPs: RPTPa (black); CD45
(red); RPTP3 (green); RPTPm (dark blue); RPTPg
(light blue). Plotted data are as in (A). Inset shows
experiments conducted with RPTPg at protein
concentrations of 0.2 (orange), 0.4 (magenta), and
0.8 (black) mg/ml. The dimer peak is indicated by
an asterisk (*).
(C) Sedimentation equilibrium analysis of RPTPg
employing a rotor speed of 7500 (black) and
10,000 rpm (red). The solid line denotes a fitted
curve resulting from global nonlinear regression
analysis with a self-association model. The resid-
uals for the fit are shown in the upper panel of the
graph. The determined dissociation constant for
the dimer was (KD) of 3.5 ± 0.3 mM.
(D) Dimer interface in the crystal structure of
RPTPg. The two molecules interact in a head-
to-toe orientation with the D1 domain (blue) of
one molecule interacting with the D2 domain (red)
of a second molecule. The catalytic cysteine
(magenta) of the D1 domain is shown in a space-
filling representation.
(E) Details of the RPTPg dimer interface. The back-
bone of the D1 domain from one molecule is
colored blue and the backbone of the D2 domain
from the interacting molecule is colored orange.
H-bonds (black) and salt-bridges (gray) are
depicted as dotted lines. See Supplemental Data
for further details.
(F) Disruption of the RPTPg dimer interface by
site-directed mutagenesis. The figure shows
sedimentation velocity data using wild-type RPTPg and RPTPg dimer interface mutants. RPTPg wild-type 0.8 mg/ml (green) and 0.4 mg/ml (black); RPTPg-
RKEE mutant 0.8 mg/ml (blue) and RPTPg-DDKK mutant 0.4 mg/ml (red) are shown. The dimer peak is indicated by an asterisk (*).correlate closely within their respective subgroups. It is therefore
unlikely that the obtained data are influenced by the chosen
domain boundaries or the presence of epitope tags in some
proteins. In addition, all analyzed proteins had crystallization
grade purity. The finding that specific activity of PTPs varies
markedly across the PTP family implies that catalytic activity
provides a mechanism of regulation in itself. All members of
the R3 subgroup as well as RPTPg were highly active, and it
will be interesting to establish how this activity is regulated
in vivo. In the case of RPTPg, which had the highest enzymatic
activity in our panel, the observed head-to-toe dimerization
might provide such an inactivating mechanism. In contrast R1
group members (e.g., CD45) and R2B group had a more than
two orders of magnitude lower enzymatic activity, suggesting
that enhancement of activity by tight association with substrates
in signaling complexes may be important for efficient signaling.
RPTPa, RPTP3, and RPTPs displayed a more limited peptiderecognition capacity in vitro, which may be related to the pres-
ence of a bulky residue in the gateway region. RPTPs showed
a preference for a sequence derived from a phosphorylation
site in N-cadherin (pY785), consistent with the recent identifica-
tion of N-cadherin as an in vivo RPTPs substrate (Siu et al.,
2007).
Remarkably PTPD1, PTPD2, and HDPTP were completely
inactive against all peptides, even at high enzyme concentra-
tions. Mass spectrometry confirmed that the protein mass corre-
sponds to the expected mass, ruling out oxidation as an expla-
nation for the lack of activity. Also, analysis of multiple PTPD1,
PTPD2, and HDPTP constructs over a pH range (pH 5.5–8.2)
gave similar results and the crystal structure of PTPD2 (Barr
et al., 2006) confirmed correct folding of the PTP domain. Exam-
ination of the protein sequence indicates that these phospha-
tases contain one or more atypical residues in the conserved
phosphotyrosine recognition loop (KNRY), the WPD loop, andCell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc. 359
the phosphate-binding loop (Andersen et al., 2001). The lack of
PTPD2 activity toward phosphopeptides is likely due to the
absence of a tyrosine residue in the phosphotyrosine recognition
loop that has the function of stabilizing binding of the substrate
pY via a p-p stacking interaction. Both PTPD1 and HDPTP
have a variation in the highly conserved WPD loop sequence
where a glutamate replaces the conserved aspartate residue. It
is likely that this sequence change is critical since this mutation
has been shown to reduce enzymatic activity by three orders
of magnitude in PTP1B (Flint et al., 1997), and the WPE loop
sequence is found in several RPTP D2 domains with negligible
catalytic activity. HDPTP has a further sequence change
(alanine/serine) in the phosphate-binding loop that resembles
the inactive pseudophosphatases IA2/IA2b.
Several earlier publications agree with our in vitro findings
(Cao et al., 1998; Ogata et al., 1999; Jui et al., 2000), but studies
demonstrating activity in vivo have also been reported. For
instance phosphatase activity of PTPD1 has been shown to
regulate EGFR and SRC signaling (Cardone et al., 2004) and
b-catenin has been reported as a substrate of PTPD2 in endothe-
lial cells (Wadham et al., 2003). These PTPs might therefore be
activated by a mechanism that remains to be elucidated.
Previously it was reported that the phosphatase PTPRQ
(PTPS31), which contains glutamate instead of aspartate in the
WPD loop, dephosphorylates phospholipids in preference to
phosphopeptides (Oganesian et al., 2003). Based on this report,
we assayed PTPD1, PTPD2, and HDPTP against a number of
phospholipid and inositol phosphates; however, none of
the three phosphatases exhibited activity toward these potential
substrates (data not shown). Thus, PTPD1, PTPD2, and HDPTP
are highly specific for certain phosphotyrosine peptide
substrates, act on so far unidentified substrates, or are intrinsi-
cally inactive phosphatases that function by noncatalytic means
as has been described for IA2b (Mziaut et al., 2006).
Regulation by Dimerization
Our structural analysis of single- and tandem-domain RPTPs
together with biophysical studies and prior structural information
from CD45 and LAR (Nam et al., 1999, 2005) reveal that PTP
catalytic domains do not dimerize in solution under physiological
buffer conditions and provide strong evidence against the long-
held inhibitory wedge model. The inhibited dimeric state
involving the N-terminal wedge, as defined in the RPTPa crystal
structure, is not present in any other PTP structure. Moreover,
analysis of tandem-domain structures showed that the orienta-
tion of D1 and D2 domains is highly conserved and is incompat-
ible with the inhibitory wedge model due to a steric clash of D2
domains (Supplemental Data). In the present study we showed
that this is also true for RPTP3, which is in the R4 subgroup
together with RPTPa, the prototype of the inhibitory wedge
model. All constructs used encompass the sequence corre-
sponding to the N-terminal helix-turn-helix, i.e., the ‘‘N-terminal
wedge,’’ of RPTPa D1. The secondary structure of this region
(i.e., helix-turn-helix) is conserved in all classical PTPs, including
RPTPg, although amino acid residue conservation is low. The
protein concentration (1 mg/ml, 15–30 mM) used in our studies
corresponds to an estimate of the RPTP concentration in
a membrane (10 mM). Although we conclude that PTP catalytic360 Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc.domains do not dimerize in solution, regulation of RPTPs by
dimerization may occur in vivo through other means involving
transmembrane domains, juxtamembrane regions (Gross et al.,
2002), or extracellular ligands (Lee et al., 2007), proteolysis of
the D1-D2 linker (Sonnenburg et al., 2003), or upon oxidation
(Blanchetot et al., 2002; Groen et al., 2008; Tonks, 2005). In
support of these data we observed dimerization of RPTPa under
oxidizing conditions (Supplemental Data).
In contrast tootherRPTPs,RPTPgdidself-associate strongly in
solutionandadimerichead-to-toearrangementofmoleculeswas
observed in the crystal structure. Mutation of residues from both
the D1 and the D2 dimer interfaces abolished dimerization con-
firming that the molecular basis for the dimerization observed in
solution correlates with the dimer model suggested by the crystal
structure (Figure 6). Our model predicts that RPTPg mutants
would have greater catalytic activity than thewild-type at concen-
trations that promote dimerization; however direct comparison at
high concentration was not feasible due to assay limitations. A
head-to-toe dimerization model involving RPTPd and RPTPs
has also been suggested based on yeast two-hybrid studies
with individual D1 and D2 domains (Wallace et al., 1998). We did
not analyze heterodimerization in this study; however, analysis
of surface electrostatics suggests that the molecular interaction
we observe for RPTPg is not directly applicable to other RPTPs.
For RPTPz, extracellular ligands have been identified including
the heparin-binding growth factors, pleiotrophin, and the cyto-
toxin VacA secreted by Helicobacter pylori (Fujikawa et al.,
2003; Maeda et al., 1999), and it has been reported that ligand
binding induces dimerization and inactivation of RPTPz resulting
in an increase in tyrosinephosphorylation of its substrate proteins
such as b-catenin, Fyn, andGIT1 (Fukada et al., 2006; Nakamura
et al., 2003; Perez-Pinera et al., 2007). Given the high sequence
identity betweenRPTPzandRPTPg it is likely that bothmolecules
are regulated in a similar manner and key residues of the dimer
interaction are conserved between these two phosphatases
(Supplemental Data). In our AUC studies, the dual-domain of
RPTPg dimerizes with a dissociation constant (KD) of 3.5 ±
0.3 mM,which is within the estimated plasmamembrane concen-
tration of 10 mM based on an estimate of 10,000 RPTPg mole-
cules in a cell. It is likely that an equilibrium exists between the
monomeric and dimeric states in the membrane, and ligand
binding to extracellular regions would shift the equilibrium to
the dimeric inactive state in which the active site is inaccessible.
Our proposed regulatory model (Figure 7) does not involve reor-
ganization of the D1-D2 domain interaction but requires flexibility
in the linker between the transmembrane domain and the first D1
phosphatase domain. The 86 residue linker between the plasma
membrane and start of the D1 domain is sufficiently long to allow
for the required flex/turn to accommodate this model. However,
future studies are necessary to establish this molecular mecha-
nism in vivo as a form of inhibitory regulation.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Expression constructs were amplified and subcloned into pGEX-6P2 vector
(AmershamBiosciences), which incorporates a PreScission protease cleavage
site, for expression as glutathione-S-transferase fusions or into modified pET
vectors (Supplemental Data). The modified pET vectors with a LIC cloning site
incorporate an N-terminal 63 His tag (pLIC-SG1, pNIC28-Bsa4) with a TEV
cleavage site (MHHHHHHSSGVDLGTENLYFQ*SM) or a C-terminal 63 His
tag (pNIC-CH) without a cleavage site (AHHHHHH). All constructs were verified
by sequencing. Expression constructswere transformed intoE. coliBL21(DE3)
and proteins were purified according to previously described procedures
(Eswaran et al., 2006; see also Supplemental Data). Mass spectrometry on
an LC-ESI-MS-tof was used to confirm the identity of the purified protein. Infor-
mation on individual proteins is compiled in the Supplemental Data.
Enzymatic Assays
Phosphatase activity against phosphopeptides was measured using the Enz-
Check (Invitrogen) continuous spectrophotometric assay (Webb, 1992). Reac-
tions were measured in a 384 well plate in 80 ml containing 50 mM Tris-HCl,
pH 7.4, 1 mMMgCl2, 50 mMNaCl, 1mMDTT, 200 mMMESG (2-amino-6-mer-
capto-7-methylpurine riboside), 1 U/ml PNP, 125 mM of the phosphopeptide
and PTP concentrations as shown in Figure 5. Absorbances were measured
continuously at 360 nm using a Spectramax plate reader at room temperature
and initial linear reaction rates were calculated over a 5 min reaction. Specific
activity toward 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) was
measured in 384 well plate format using a buffer containing 25 mM MOPS,
pH 7, 50 mM NaCl, and 1 mM DTT and excitation and emission wavelengths
of 355 nm and 460 nm, respectively (see Supplemental Data for further details).
Analytical Ultracentrifugation
Sedimentation velocity experiments were carried out on a Beckman XL-I
Analytical Ultracentrifuge. Protein samples were studied at concentrations of
0.2–0.8 mg/ml in 10 mM HEPES (pH 7.5), 150 mM NaCl, and 1 mM TCEP at
8C, employing a rotor speed of 50,000 rpm. Absorbance data were analyzed
with SEDFIT version 9.4 (Schuck, 2000) calculating c(s) distributions. Equilib-
rium experiments were performed at three protein concentrations (0.2, 0.4,
and 0.8 mg/ml) and two centrifugation speeds (7500 rpm and 10,000 rpm),
and data were evaluated by using the software package Ultraspin (Dimitry
Veprintsev, MRC Centre for Protein Engineering).
Crystallization and Structure Determination
Individual proteins were crystallized in sitting drops at either 4Cor 20C. Crys-
tals were cryoprotected and flash frozen, and X-ray diffraction data were
collected at 100 K on beam lines X10SA at the Swiss Light Source (SLS), on
beam line 14.1 at the Berliner Elektronenspeicherring-Gesellschaft fu¨r Syn-
chrotronstrahlung (BESSY), and at a Rigaku FRE Superbright home source.
Diffraction images were indexed and integrated using MOSFLM (Leslie,
1992) or DENZO in HKL2000 (Otwinowski and Minor, 1997) or XDS (Kabsch,
1993) and data were scaled using SCALA, SCALEPACK in HKL2000, or
XSCALE, respectively. Structures were solved by molecular replacement
using PHASER (McCoy et al., 2007) and were refined against maximum likeli-
hood targets using restrained refinement and TLS protocols implemented in
REFMAC (Murshudov et al., 1997). Iterative rounds of refinement were inter-
spersed with manual rebuilding in COOT (Emsley and Cowtan, 2004). Addi-
tional information is compiled in the Supplemental Data and is also available
at http://www.sgc.ox.ac.uk/research/phosphatases.
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Figure 7. Schematic Model of RPTPg Dimerization-Induced Inactivation
The proposed transition of RPTPg from monomer to dimer on ligand binding is shown. The carbonic anhydrase (CA), fibronection (FN), and intracellular tandem
phosphatase (D1 and D2) domains are represented as low-resolution surfaces. Surface representations are based on PDB codes: 1JDO for the carbonic
anhydrase domain, 2GEE for the fibronectin domain, and 2NLK for the tandem-phosphatase domain. In the monomeric state, the active site of RPTPg (red)
is accessible and the phosphatase is active. Ligand binding to the extracellular part of RPTPg brings two molecules into close proximity and consequently
the phosphatase domains dimerize in a head-to-toe arrangement as in the RPTPg crystal structure with the D2 domain of one molecule blocking the active
site (D1) from a second molecule, leading to suppression of phosphatase activity.Cell 136, 352–363, January 23, 2009 ª2009 Elsevier Inc. 361
(PTPRE, RPTP3); 2PA5 (PTPN9, MEG2); 2B49 (PTPN3, PTPH1); 2I75 (PTPN4,
MEG1); 3B7O (PTPN11, SHP2 D1); 2A8B (PTPRR, PCPTP1); 2QEP (PTPRN2,
IA2b); 2P6X (PTPN22, LYP); 2BZL (PTPN14, PTPD2); 2BIJ (PTPN5, STEP);
2BV5 (PTPN5, STEP); 2CJZ (PTPN5, STEP-Cys/Ser mutant & pY); 2A3K
(PTPN7, HePTP); 2C7S (PTPRK, RPTPk); 2OOQ (PTPRT, RPTPr); 2NLK
(PTPRG, RPTPg D1-D2); 2H4V (PTPRG, RPTPg D1); 2AHS (PTPRB, RPTPb);
2GJT (PTPRO, GLEPP1); 2NZ6 (PTPRJ, DEP1-Cys/Ser mutant); 2CFV
(PTPRJ, DEP1-Trp/Ala mutant).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, five
figures, and five tables and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(08)01513-4.
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